Perfil dos hormônios da tireoide em pacientes com câncer de mama em estado de menopausa

Conde, Sandro José; Luvizotto, Renata de Azevedo Melo; Síbio, Maria Teresa De; Saraiva, Patrícia Pinto; Brentani, Maria Mitzi; Nogueira, Célia Regina

doi:10.1590/s0004-27302012000400004

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Foi observado níveis mais elevados de t4 livre. Os autores concluem que os resultados reforçam a necessidade da avaliação do perfil tireoidiano em portadoras de câncer de mama (CONDE et al, 2012).…”

Section: Introductionunclassified

Estudo da prevalência de doença autoimune da tireóide em portadoras de câncer de mama

Freitas¹

View full text Add to dashboard Cite

Breast cancer is a hormone-dependent neoplasia. In addition to the fact that breast cancer and thyroid disease are more prevalent in the fifth and sixth decades of life, several studies also suggest an association between these two disorders. The aim of this study was to analyze the prevalence of thyroid disorders in patients with a positive biopsy for breast cancer prior to specific antitumor treatment. The frequency and pattern of thyroid disorders were evaluated in 112 patients with breast cancer (G1) and 125 control patients (G2) by analyzing serum thyroidstimulating hormone (TSH), anti-thyroid peroxidase (anti-TPO) antibodies and antithyroglobulin (anti-Tg) antibodies. In addition, the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) was assessed in the breast biopsies by immunohistochemistry. The frequency of thyroid disorders, such as changes in TSH levels and/or the presence of positive thyroid antibodies, was not different between the two groups examined (30.4% in G1 and 28.0% in G2) (p=0.69). However, a family history of thyroid disease was more frequent in patients with breast cancer (50.5% in G1 and 28.2% in G2) (p=0.001). Regarding the clinical stage of breast cancer, there was no difference between women with autoimmune thyroiditis and those without thyroid dysfunction (p=0.316). Similarly, there were no differences in hormone receptor (estrogen and progesterone) and HER2 expression between patients who tested positive and negative for antithyroid antibodies (p=0.052 and p=0.549). The data obtained in this study did not reveal a higher frequency of autoimmune thyroid disease in patients with breast cancer compared to controls, and the prevalence of thyroid disorders was similarly elevated in both groups.However, a family history of thyroid disease was higher in those with cancer.

show abstract

Section: Introductionunclassified

Estudo da prevalência de doença autoimune da tireóide em portadoras de câncer de mama

Freitas¹

View full text Add to dashboard Cite

show abstract

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

et al. 2016

Self Cite

View full text Add to dashboard Cite

High expression levels of hypoxia inducing factor 1 alpha are related to mammary carcinogenesis. In previous studies, we demonstrated that expression of transforming growth factor alpha increases upon treatment with triiodothyronine, but this expression does not occur in cellular models that do not express the estrogen receptor, or when cells are co-treated with the anti-estrogen, tamoxifen. The aim of this study was to determine the effect of the hormone triiodothyronine on the expression of the genes HIF1A and TGFA in the breast cancer cell line MCF7. The cell line was subjected to treatment with triiodothyronine at the supraphysiological dose of 10(-8)M for 10min, 30min, 1h, and 4h in the presence or absence of actinomycin D, the gene expression inhibitor, cycloheximide, the protein synthesis inhibitor, and LY294002, the phosphoinositide 3 kinase inhibitor. HIF1A and TGFA mRNA expression was analyzed by reverse transcription polymerase chain reaction. For data analysis, we used analysis of variance complemented by Tukey test and an adopted minimum of 5% significance. We found that HIF1A and TGFA expression increased in the presence of triiodothyronine at all times studied. HIF1A expression decreased in triiodothyronine-treated cells when gene transcription was also inhibited; however, TGFA expression decreased after 10 and 30min of treatment even when transcription was not inhibited. We found that activation of PI3K was necessary for triiodothyronine to modulate HIF1A and TGFA expression.

show abstract

Perfil dos hormônios da tireoide em pacientes com câncer de mama em estado de menopausa

Cited by 2 publications

References 36 publications

Estudo da prevalência de doença autoimune da tireóide em portadoras de câncer de mama

Estudo da prevalência de doença autoimune da tireóide em portadoras de câncer de mama

Triiodothyronine (T3) induces HIF1A and TGFA expression in MCF7 cells by activating PI3K

Contact Info

Product

Resources

About